Potential "best-in-class"! The third generation APK inhibitor of Tagri Bio was approved clinically

On December 17th, according to the Drug Review Center (CDE) of the State Drug Administration of China, Tagri Bio obtained two clinical trials with TGRX-326 tablets submitted in category 1 of the chemical, with the proposed development of analyte as ALK-positive or/or ROS1-positive advanced non-small cell lung cancer (NSCLC).
, TGRX-326 is the third generation of ALK high-efficiency inhibitors that target the EML4-ALK fusion gene, according to publicly available data.
Screenshot Source: TGRX-326 is a new generation of powerful inhibitors used to treat mesolytic lymphoma kinase (ALK) positive NSCLC, with the potential to become a "best-in-class" that promises to bring new treatments to lung cancer patients, according to an earlier press release from Tagri Bio.
addition, it is able to pass through the blood-brain barrier and is expected to have excellent results in patients with advanced lung cancer brain metastasis.
APK is a more common target in non-small cell lung cancer, accounting for about 3% to 8%.
, TGRX-326 can effectively overcome the existing drug resistance problems, especially for the first and second generation resistance ALKG1202R mutation effective.
preclinical studies have shown that TGRX-326's new, unique drug structure makes it highly active and highly selective for wild and most mutant APK kinases.
, it also has specific biological activity for ROS1 kinase, which can be used to treat non-small cell lung cancer caused by ROS1 fusion gene-positive.
founded in 2014 by Dr. Wang Yihan,
Tagery Bio is dedicated to challenging the medical challenges of cancer access resistance and developing the latest generation of small molecule-targeted and innovative drugs for cancer treatment with independent intellectual property protection.
In September, the company completed nearly 100 million yuan of strategic financing, which will be used primarily for clinical research on the fourth generation Bcr-Abl inhibitor TGRX-678 and the next-generation inhibitor TGRX-326, as well as research and development of other next-generation targeted drugs.
TGRX-326 and TGRX-678 will conduct their first human trials in early 2021, according to the Tagire Bio news release.
References: China's State Drug Administration Drug Review Center. Retrieved Dec 17, 2020, from the latest generation of ALC inhibitor TGRX-326 for tager non-small cell lung cancer was accepted by CDE. Retrieved Oct 17, 2020, from Tagery's latest generation of non-small cell lung cancer APK inhibitors obtained clinical license in China . Retrieved Dec 17, 2020, from Source: Medical Mission Hills